Nordson Corporation (NDSN) Earnings

Management highlights

- Overall Company Performance * The company delivered record Q3 2026 sales of $818 million, a 10% year-over-year increase, with 12% organic growth. Order entry momentum accelerated, driving total backlog up 35% year-over-year, with particular strength from ATS and MFS. * Record profit results: EBITDA reached $262 million (32% of sales, all-time record), adjusted earnings per share hit $3.25 (all-time record, 19% year-over-year increase, 10 cents above the high end of prior guidance). * Free cash flow was $237 million, with a 144% free cash flow conversion rate on net income (excluding non-cash charges), marking the fifth consecutive quarter of over 100% conversion. Net debt decreased to $1.6 billion, with a leverage ratio of 1.7x, driven by strong cash generation. * Year-to-date through nine months, revenue grew 9% and adjusted EPS grew 18% year-over-year. Capital allocation is balanced: $40 million invested in capital projects, $137 million paid in dividends, $159 million used for share repurchases, all while reducing net debt. - Strategic Positioning * The company's long-term competitive advantage is built on three core themes: differentiated products, close customer relationships, and a diversified portfolio of niche markets. The NBS Next decentralized operating framework focuses on high-growth opportunities to deliver above-market organic growth. * Approximately 60% of the portfolio generates recurring revenue (aftermarket parts, consumables, services), and over 50% of the portfolio is exposed to high-growth end markets (semiconductor, electronics, medical), with the remainder in stable GDP-aligned end markets, reducing overall cyclicality. * Execution of the Ascend strategy has reduced lead times and improved on-time delivery to 80-95% across most divisions, enabling market share gains.

Guidance

- Management increased full fiscal year 2026 guidance based on sustained order momentum and strong delivery execution. * New full year sales guidance is $3.35 billion to $3.75 billion. * New full year adjusted diluted EPS guidance is $11.80 to $12.00, placing results at the high end of the company's previous average growth algorithm. * The updated guidance assumes current FX rates hold, implying a neutral currency impact for the fourth quarter. * The full year adjusted effective tax rate is expected to be near 18%, which is management's long-term expected run rate.

Segment performance

1. Industrial Precision Solution (IPS): Total sales were $367 million, a 5% year-over-year increase, representing 44.9% of total company revenue. Organic sales increased 3% year-over-year, with 1% from favorable currency and 1% from acquisition contributions. EBITDA was $130 million, equal to 35% of segment sales, flat year-over-year. 2. Medical and Fluid Solution (MFS): Total sales were $231 million (a quarterly record), a 5% year-over-year increase, representing 28.2% of total company revenue. Organic sales increased 11% year-over-year, partially offset by a 6% negative impact from the divested medical contract manufacturing business. EBITDA was a record $88 million, equal to 38% of segment sales, a 6% year-over-year increase and 100 basis points of sequential margin improvement. 3. Advanced Technology Solution (ATS): Total sales were $220 million (an all-time quarterly record), a 28% year-over-year increase, representing 26.9% of total company revenue. Organic sales increased 31% year-over-year, with broad growth across electronics dispense and test and inspection product lines driven by semiconductor and broader electronics demand. EBITDA was an all-time quarterly record of $66 million, equal to 30% of segment sales, a 58% year-over-year increase from $42 million (24% of sales) in the prior year quarter.

Risks & headwinds

- Forward-looking statements are subject to general risks and uncertainties detailed in the company's SEC filings that could cause actual results to differ materially from expectations. * Broad-based inflationary pressures linked to market and geopolitical factors persist, impacting input costs such as freight and selected commodities, though management has been effective at mitigating these pressures while maintaining strong margins. * Non-cash mark-to-market valuation adjustments for minority investments are subject to market volatility, though the year-to-date impact is negligible. * The ATS segment is currently experiencing above-trend growth at the peak of its current cycle, and growth is expected to normalize to long-term levels in future periods.

Analyst Q&A

• Q: Backlog grew 35% year-over-year. Is this due to longer lead times, what is the typical turnover, and what visibility does this provide? /

  A: Backlog growth is broad-based across all three segments, with no change from normal order patterns. Nordson's backlog typically turns over in approximately six months, with 80% of backlog fulfilled within that window, and only a small share of long-lead large system orders that extend beyond that. Lead times have actually shortened over time due to the Ascend strategy and operational improvements, and on-time delivery ranges from 80-95% across most divisions, a competitive strength that has driven share gains. The strong backlog provides clear visibility into results through Q4 and into 2027.

• Q: How differentiated is ATS growth versus IPS and MFS, and what is driving the guidance upgrade? /

  A: The ATS segment is growing significantly above its long-term targets at the current peak of the semiconductor/electronics cycle, driving much of the top-line upside. MFS is also seeing accelerating order momentum, growing 11% organically in Q3 against a long-term target of 6-7% annual growth. IPS, which makes up ~50% of the company, is performing exactly as expected, delivering 3% organic growth in line with its long-term targets. The guidance upgrade is driven by upside acceleration in both ATS and MFS, with no surprises from IPS.

• Q: For the ATS segment, how durable is the current growth cycle, and what is the outlook for fiscal 2027? /

  A: Current pipeline activity, order entry, backlog, and delivery momentum all indicate there is still significant room left in this growth cycle. While 2027 growth will lap the very strong 2026 results and normalize to the segment's long-term mid-single digit target, that growth will build off a new all-time peak base. A key unfulfilled demand driver is upcoming chip manufacturing infrastructure buildout in North America; most of this demand has not yet converted to orders for Nordson, creating additional upside for 2027 and beyond.

• Q: With a strong balance sheet and low leverage, what is the current M&A outlook? /

  A: M&A remains a core part of Nordson's long-term growth algorithm, targeting 50% of total growth from inorganic acquisitions over time. There is a healthy pipeline of opportunities, and management remains disciplined to only pursue deals that meet three strategic criteria (attractive niche end markets, differentiated technology, adds to the high-growth portfolio) and financial criteria (above-market growth, best-in-class margins, returns exceeding cost of capital). Management is actively focused on expanding the medical platform and adding bolt-on acquisitions to existing core franchises, particularly in test and inspection.